...We Welcome You To The Resverlogix HUB withIn The AGORACOM COMMUNITY!

Free
Message: AHA 2018

REDUCE-IT: Mixed bag. Great results for Vascepa, including 26% RRR in 3-point MACE. Substantial concern of harmful placebo effect confounds data interpretation.

CIRT:  No statistically significant effect on 3-point MACE by low dose methotrexate

DECLARE-TIMI 58: Dapagliflozin no statistically significant effect on 3-point MACE

 

Share
New Message
Please login to post a reply